SCHEMBL4863796

SCHEMBL4863796

COc1ccc(S(=O)(=O)NCC(=O)N(C)c2ccc(Cl)cc2C(O)c2ccccc2Cl)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.48
FDFT1 P37268 5/20 0.47
FLT1 P17948 1/20 0.44
FLT4 P35916 1/20 0.44
KDR P35968 1/20 0.44
PKM P14618 2/20 0.42
HCRTR2 O43614 2/20 0.42
HCRTR1 O43613 1/20 0.42
ALDH1A1 P00352 3/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3256844 0.91 MAPK1 (0.48) MAPK1FLT1FLT4KDRPKM
SCHEMBL3247585 0.90 MAPK1 (0.44) MAPK1FLT1FLT4KDRPKM
SCHEMBL4870254 0.89 FDFT1 (0.50) FDFT1
SCHEMBL3253300 0.86 PKM (0.41) MAPK1FLT1FLT4KDRPKM
SCHEMBL3247452 0.85 FDFT1 (0.49) FDFT1
SCHEMBL3253914 0.83 ALDH1A1 (0.43) MAPK1FLT1FLT4KDRPKM
SCHEMBL3263100 0.82 MAPK1 (0.57) MAPK1FLT1FLT4KDRPKM
SCHEMBL4870949 0.81 MAPK1 (0.49) MAPK1FLT1FLT4KDRPKM
SCHEMBL3247298 0.81 PKM (0.46) MAPK1FDFT1FLT1FLT4KDR
SCHEMBL4870760 0.80 FDFT1 (0.49) FDFT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 MAPK1 2674/4885FDFT1 1608/4885FLT1 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.